Abstract:
PURPOSE:The current study was initiated to assess the clinical efficacy and side effects of rituximab in patients with relapsed advanced stage follicular lymphoma. PATIENTS AND METHODS:The study was performed as an open-label non-randomized multicenter phase-II trial and included patients older than 18 years of age with relapsed advanced-stage follicular lymphomas (FL) grades I and II, according to the REAL classification, or with centroblastic/centrocytic (CB/CC lymphomas according to the Kiel classification. Four weekly doses of 375 mg/m2 rituximab were applied. RESULTS:38 patients from eight centers were included between January 1997 and January 1998 and were evaluable for response and toxicity on an intention to treat basis. The median age was 55 years (range 26-75 years). Thirteen patients (35%) were in first relapse, 11 patients (30%) in second, and 13 patients (35%) in third relapse. The median time between primary diagnosis and study entry was 4.6 years (range 0.9-14.7 years). Twenty-three patients tolerated the application of rituximab without adverse events; in 13 cases the infusion rate had to be reduced because of side effects; in two patients the application was stopped because of pharyngeal edema and anaphylactoid reaction. The most frequent side effects were fever (13 patients) and rigor (13 patients); 65% of the side effects were observed after the first infusion. Twenty grade-III/IV side effects were considered to be related to treatment: lymphocytopenia (3), granalocytopenia (1), thrombocytopenia (2), fever (1), hyperglycermia (1), venous thrombosis (1), syncope (1), plasmatic coagulation disorder (1), shortness of breath (2), photosensitivity (1), cardiac failure (1), chills (1), sepsis (1), tumor lysis (1), anemia (1), and pharyngeal edema (1). Eight patients were not eligible for assessment of response because of non-follicular subtypes of low-grade lymphomas (n =6) or early termination of therapy at the first infusion because of severe side effects (n =2). From the 30 evaluable cases with follicular lymphomas, five patients achieved a complete remission (CR) (17%), nine patients a partial remission (PR) (30%), and two patients a minor response (MR) (7%). The overall response rate was 47%. The median time to treatment progression (TTP) was 201 days (range 64-293 days), with five patients experiencing long-lasting remissions of 214-293 days duration. In three patients, the rituximab-induced remission exceeded the preceding progression-free interval substantially. Bulky disease (P=0.058) and/or bone-mar row involvement (P=0.046) were associated with poor response. CONCLUSION:This study confirms the moderate treatment-related toxicity and the high antilymphoma activity of rituximab in patients with relapsed follicular lymphoma. Further studies are needed to determine the role of rituximab in the first-line treatment of these disorders and its combination with conventional chemotherapy.
journal_name
Ann Hematoljournal_title
Annals of hematologyauthors
Feuring-Buske M,Kneba M,Unterhalt M,Engert A,Gramatzki M,Hiller E,Trümper L,Brugger W,Ostermann H,Atzpodien J,Hallek M,Aulitzky E,Hiddemann Wdoi
10.1007/s002770000163subject
Has Abstractpub_date
2000-09-01 00:00:00pages
493-500issue
9eissn
0939-5555issn
1432-0584journal_volume
79pub_type
临床试验,杂志文章abstract::We analyzed the prognostic factors for a successful mobilization and peripheral blood stem cell collection in a series of 57 consecutive patients with multiple myeloma (MM); a new scoring system to predict an adequate mobilization in this subset of patients was also constructed. A total of 221 aphereses were performed...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s002770100351
更新日期:2001-10-01 00:00:00
abstract::Patients previously diagnosed with invasive aspergillosis (IA) have been considered to be at risk for relapse of mycosis during subsequent hematopoietic transplant. Even with prophylactic measures, reactivation of the infection occurs in 29% of patients undergoing bone marrow transplantation (BMT). A period of neutrop...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s002770100311
更新日期:2001-08-01 00:00:00
abstract::Established risk factors for thrombosis in essential thrombocythemia (ET) include age (≥ 60 years) and previous vascular events. Recently, also leukocytosis has been proposed in risk stratification of ET patients. We report a retrospective study on 532 ET patients followed for a median of 7.6 years. Sixty-four patient...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-010-1154-3
更新日期:2011-08-01 00:00:00
abstract::Hematopoietic recovery after high-dose chemotherapy (HDC) in the treatment of hematological diseases may be slow and/or incomplete. This is generally attributed to progressive hematopoietic stem cell failure, although defective hematopoiesis may be in part due to poor stromal function. Chemotherapy is known to damage ...
journal_title:Annals of hematology
pub_type: 临床试验,杂志文章
doi:10.1007/s00277-009-0896-2
更新日期:2010-07-01 00:00:00
abstract::Azacitidine (AZA) is a DNA hypomethylation agent administered in myeloid neoplasms; however, there is still a lack of established predictors of response. We studied 113 patients with myelodysplastic syndromes (n = 85) or acute myeloid leukemia (n = 28) who received AZA to assess the predictive value on response of cli...
journal_title:Annals of hematology
pub_type: 临床试验,杂志文章
doi:10.1007/s00277-020-03932-8
更新日期:2020-03-01 00:00:00
abstract::Alterations in hemoglobin oxygen affinity can be detected by exposing blood to different PO2 and recording oxygen saturation, a method termed tonometry. It is the gold standard to measure the PO2 associated with 50 % oxygen saturation, the index used to quantify oxygen affinity (P50Tono). P50Tono is used in the evalua...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-012-1667-z
更新日期:2013-04-01 00:00:00
abstract::We evaluated the clinical features, treatment modalities, treatment responses, and prognosis of our patients with immune thrombocytopenia (ITP). Furthermore, we estimated the frequency of ITP in the Thrace region of Turkey. Two hundred sixteen patients diagnosed with ITP between 2000 and 2012 at our center were retros...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-014-2220-z
更新日期:2015-03-01 00:00:00
abstract::We describe a unique case of IgG lambda myeloma in which a plasma cell leukemia developed and the paraprotein changed from IgG lambda to lambda chain, the latter inducing fatal renal failure. In addition, J-chain was detected in the cytoplasm of the plasma cell leukemia cells. ...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/BF01703239
更新日期:1993-04-01 00:00:00
abstract::Extramedullary (e) relapse in multiple myeloma(MM) has an adverse prognosis, but knowledge concerning biological features and preferred treatment is scarce. We screened the myeloma registry of our institution for eMM relapses and identified 24 cases among 357 patients (pts).Only 8% of eMM relapses occurred after initi...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-012-1414-5
更新日期:2012-07-01 00:00:00
abstract::Chronic idiopathic neutropenia of adults (CINA) is a granulocytic disorder characterised by the "unexplained" decrease in the number of circulating neutrophils. Serum inflammatory cytokines and chemokines are increased in CINA. In addition, cytokines gene polymorphisms are associated with increased levels of respectiv...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-005-1066-9
更新日期:2005-10-01 00:00:00
abstract::In some instances, because of the lack of mass formation and the absence of prominent lymph node enlargement, diagnosis of lymphoma-associated hemophagocytic syndrome (LAHS) is difficult, which results in the development of progressive disease with unfavorable prognosis. Therefore, in the diagnosis of secondary hemoph...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-011-1239-7
更新日期:2012-01-01 00:00:00
abstract::Elderly and infirm patients with acute myeloid leukemia (AML) with either induction refractory or relapse disease may benefit from treatment with azacitidine. We retrospectively reviewed the data from five tertiary centers in Israel, treated between 2009 and 2015. Thirty-four patients (median age 74 years) were identi...
journal_title:Annals of hematology
pub_type: 杂志文章,多中心研究
doi:10.1007/s00277-016-2914-5
更新日期:2017-04-01 00:00:00
abstract::Bortezomib synergizes with melphalan in preclinical and early clinical studies. Updated data from our phase 1/2 study assessing the safety and efficacy of bortezomib plus melphalan in relapsed/refractory multiple myeloma (MM) are presented. Bortezomib (0.7, 1.0, or 1.3 mg/m(2)) on days 1, 4, 8, and 11 and oral melphal...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-008-0501-0
更新日期:2008-08-01 00:00:00
abstract::Bone marrow transplantation (BMT) and immunosuppression (IS) have improved the prognosis of aplastic anemia; both treatments have specific advantages and drawbacks but similar survival rates. Analysis of additional endpoints may help in treatment decisions. In a single-center study, patients with aplastic anemia treat...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-004-0930-3
更新日期:2005-01-01 00:00:00
abstract::The rarity of severe complications of this disease in children makes randomized clinical trials in immune thrombocytopenia (ITP) unfeasible. Therefore, the current management recommendations for ITP are largely dependent on clinical expertise and observations. As part of its discussions during the Intercontinental Coo...
journal_title:Annals of hematology
pub_type: 共识发展会议,杂志文章
doi:10.1007/s00277-010-0941-1
更新日期:2010-07-01 00:00:00
abstract::High-dose chemotherapy (HDT) and stem cell transplantation is a newer treatment option widely applied in poor-risk germ cell tumor patients. Due to the increasing practical clinical experience and the availability of hematopoietic growth factors, this treatment approach has become a relatively safe procedure. Dependin...
journal_title:Annals of hematology
pub_type: 杂志文章,评审
doi:10.1007/s002770050386
更新日期:1998-05-01 00:00:00
abstract::Immune thrombocytopenia (ITP) is characterised by a transient or persistent decrease in platelets accompanied by an increased risk of bleeding, which can have a significant negative impact on patients' health-related quality of life. The condition has long been associated with an increased rate of immune-mediated plat...
journal_title:Annals of hematology
pub_type: 杂志文章,评审
doi:10.1007/s00277-010-0953-x
更新日期:2010-07-01 00:00:00
abstract::Venous thromboembolism (VTE) is a well-recognized complication in pediatric oncology patients. Studies in adult oncology patients have suggested a potential negative association between VTE and survival, but this association has not been examined in pediatric patients yet. The aim of this study was to assess the assoc...
journal_title:Annals of hematology
pub_type: 杂志文章,多中心研究
doi:10.1007/s00277-018-3371-0
更新日期:2018-10-01 00:00:00
abstract::The JAK2V617F mutation is part of the major criteria for diagnosis of myeloproliferative neoplasms (MPN). Allele-specific quantitative PCR (qPCR) is the most prevalent method used in laboratories but with the advent of next-generation sequencing (NGS) techniques, we felt necessary to evaluate this approach for JAK2 mu...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-018-3499-y
更新日期:2019-01-01 00:00:00
abstract::The combination of sickle cell disease crisis and thrombotic thrombocytopenic purpura has been described only a few times. Here we present the case of a patient with a hemolytic crisis due to sickle cell disease complicated by thrombotic thrombocytopenic purpura. We also review the cases previously reported and compar...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s002770050558
更新日期:1999-12-01 00:00:00
abstract::The clinical course of three patients with acute promyelocytic leukemia receiving all-trans retinoic acid (ATRA) as a single agent is reported. The first two patients were in first and second relapse of their leukemia that had occurred despite maintenance treatment with 13-cis retinoic acid after chemotherapy-induced ...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/BF01695469
更新日期:1992-06-01 00:00:00
abstract::The efficacy of a single dose of MCNU 150 mg was evaluated in nine symptomatic patients with essential thrombocythemia (ET). As the platelet counts increased during the following 4 weeks, an extra dose of 100 mg of MCNU was administered to three patients. All patients had thrombotic or hemorrhagic complications. Seven...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/BF01738474
更新日期:1993-05-01 00:00:00
abstract::An additional affiliation for the first author was not indicated. Hyewon Lee is also affiliated with: Department of Internal Medicine, Yonsei University College of Medicine, Gangnam Severance Hospital, Seoul, South Korea. ...
journal_title:Annals of hematology
pub_type: 杂志文章,已发布勘误
doi:10.1007/s00277-019-03868-8
更新日期:2020-01-01 00:00:00
abstract::Neutrophil-lymphocyte ratio (NLR), an indicator of inflammation, has been lately demonstrated as a prognostic factor and an indicator of disease activity in various diseases. However, the effects of NLR have not been investigated in mycosis fungoides (MF) patients yet. The aim of this study is to investigate the relat...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-016-2779-7
更新日期:2016-10-01 00:00:00
abstract::The aim of the present study was to investigate the prognostic role of pre- and/or early post-autologous stem cell transplantation (ASCT) (18)F-flourodeoxyglucose (FDG) positron emission tomography (PET) in patients with relapsed/refractory Hodgkin lymphoma. Forty-three consecutive patients were enrolled in this study...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-011-1209-0
更新日期:2011-11-01 00:00:00
abstract::This study outlines trends in quality of delivered non-Hodgkin's lymphoma (NHL) care in the Netherlands between 2007 and 2011 and to what extend this was influenced by the national Visible Care program, which aimed at increasing transparency by providing insight into the quality of healthcare. We analyzed data collect...
journal_title:Annals of hematology
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1007/s00277-015-2340-0
更新日期:2015-07-01 00:00:00
abstract::The anti-CD38 monoclonal antibody daratumumab is approved as a single agent for the treatment of patients with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent (IMID), or who are double refractor...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-019-03655-5
更新日期:2019-06-01 00:00:00
abstract::Aplastic anaemia (AA) is a rare bone marrow failure syndrome treated either by immunosuppressive therapy or allogeneic stem cell transplantation (SCT). At present, no randomised clinical trials evaluating both treatment options, and in particular SCT from unrelated donors, are available. We here report the clinical co...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-008-0466-z
更新日期:2008-07-01 00:00:00
abstract::Multicentric Castleman's disease (MCD) is a rare systemic lymphoproliferative disorder with too few patient series reported in the literature to have a clear idea about the etiology, outcome and the best treatment available. Systemic reactive amyloidosis is a very rare complication of MCD and its presence worsens the ...
journal_title:Annals of hematology
pub_type: 杂志文章
doi:10.1007/s00277-003-0718-x
更新日期:2003-12-01 00:00:00
abstract::Autosomal recessive "malignant" osteopetrosis is a rare congenital disorder relating to bone resorption abnormalities. It is believed to arise due to the failure of osteoclasts to resorb immature bone. This leads to abnormal bone marrow cavity formation and, clinically, to the signs and symptoms of bone marrow failure...
journal_title:Annals of hematology
pub_type: 杂志文章,评审
doi:10.1007/s00277-002-0578-9
更新日期:2003-01-01 00:00:00